Ingenol Mebutate Gel
Total Payments
$708,221
Transactions
78
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $708,221 | 78 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $708,221 | 78 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 094-8152-301 | Teva Pharmaceuticals USA, Inc. | $708,221 | 3 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $708,221
Product Information
- Type Drug
- Total Payments $708,221
- Total Doctors 3
- Transactions 78
About Ingenol Mebutate Gel
Ingenol Mebutate Gel is a drug associated with $708,221 in payments to 3 healthcare providers, recorded across 78 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $708,221 was paid across 78 transactions to 3 doctors.
The most common payment nature for Ingenol Mebutate Gel is "Unspecified" ($708,221, 100.0% of total).
Ingenol Mebutate Gel is associated with 1 research study, including "094-8152-301" ($708,221).